BLUETTI Helps Create the Best Valentine's Day Experience 10-02-2023, 12:00

IIBA Launches Enhanced Career Center and Job Board Targeting Business Analysis Opportunities 8-02-2023, 21:00

Io Therapeutics, Inc., presented data from studies of IRX4204, the company’s phase II clinical development stage, highly selective third generation RXR nuclear receptor agonist compound, supporting its potential use for prevention and treatment of normal 10-07-2024, 07:00